Involvement of anticancer drugs in the relief system for adverse drug reactions in Japan

Hideki Maeda, Tatsuo Kurokawa

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Objective: The compensation scheme for adverse drug reactions in Japan was implemented more than three decades ago as relief system by regulatory agencies. Because of the high frequency of adverse drug reactions, anticancer drugs have been excluded from coverage by the relief system since its implementation. Requests have recently been made by some patient advocates for the expansion of relief coverage to include anticancer drugs. In response to these requests, the Ministry of Health, Labor and Welfare of Japan established a committee to discuss relief from anticancer drug-induced health damages in June 2011. Methods: We conducted comprehensive research into the compensation scheme for adverse drug reactions in the world.We also investigated the situation of compensation and the committee for discussing inclusion of anticancer drugs into the relief system in Japan. Results: Many countries including the United States and UK do not have relief or compensation schemes for no-fault compensation. We investigated whether a no-fault compensation system exists in Nordic countries (Sweden, Denmark, Norway and Finland), France, Germany, New Zealand and Taiwan in the world, although they offer different services from Japan.We also reviewed current situation and the fundamental difficulties associated with including anticancer drugs in the systems in Japan. Conclusions: The present study investigated the current situation and the fundamental difficulties associated with including anticancer drugs in the systems in Japan and pointed out part of the reason why the committee could not conclude involvement of anticancer drugs in the relief system.

Original languageEnglish
Article numberhyt146
Pages (from-to)1273-1281
Number of pages9
JournalJapanese Journal of Clinical Oncology
Volume43
Issue number12
DOIs
Publication statusPublished - 2013 Dec

Fingerprint

Drug-Related Side Effects and Adverse Reactions
Japan
Pharmaceutical Preparations
Scandinavian and Nordic Countries
Health
Denmark
Finland
Norway
Taiwan
New Zealand
Sweden
France
Germany
Research

Keywords

  • Adverse drug reactions
  • Anticancer drug
  • Compensation
  • Oncology
  • Relief system

ASJC Scopus subject areas

  • Oncology
  • Cancer Research
  • Radiology Nuclear Medicine and imaging

Cite this

Involvement of anticancer drugs in the relief system for adverse drug reactions in Japan. / Maeda, Hideki; Kurokawa, Tatsuo.

In: Japanese Journal of Clinical Oncology, Vol. 43, No. 12, hyt146, 12.2013, p. 1273-1281.

Research output: Contribution to journalArticle

@article{b885552b464240c9b16d6a545853e6e0,
title = "Involvement of anticancer drugs in the relief system for adverse drug reactions in Japan",
abstract = "Objective: The compensation scheme for adverse drug reactions in Japan was implemented more than three decades ago as relief system by regulatory agencies. Because of the high frequency of adverse drug reactions, anticancer drugs have been excluded from coverage by the relief system since its implementation. Requests have recently been made by some patient advocates for the expansion of relief coverage to include anticancer drugs. In response to these requests, the Ministry of Health, Labor and Welfare of Japan established a committee to discuss relief from anticancer drug-induced health damages in June 2011. Methods: We conducted comprehensive research into the compensation scheme for adverse drug reactions in the world.We also investigated the situation of compensation and the committee for discussing inclusion of anticancer drugs into the relief system in Japan. Results: Many countries including the United States and UK do not have relief or compensation schemes for no-fault compensation. We investigated whether a no-fault compensation system exists in Nordic countries (Sweden, Denmark, Norway and Finland), France, Germany, New Zealand and Taiwan in the world, although they offer different services from Japan.We also reviewed current situation and the fundamental difficulties associated with including anticancer drugs in the systems in Japan. Conclusions: The present study investigated the current situation and the fundamental difficulties associated with including anticancer drugs in the systems in Japan and pointed out part of the reason why the committee could not conclude involvement of anticancer drugs in the relief system.",
keywords = "Adverse drug reactions, Anticancer drug, Compensation, Oncology, Relief system",
author = "Hideki Maeda and Tatsuo Kurokawa",
year = "2013",
month = "12",
doi = "10.1093/jjco/hyt146",
language = "English",
volume = "43",
pages = "1273--1281",
journal = "Japanese Journal of Clinical Oncology",
issn = "0368-2811",
publisher = "Oxford University Press",
number = "12",

}

TY - JOUR

T1 - Involvement of anticancer drugs in the relief system for adverse drug reactions in Japan

AU - Maeda, Hideki

AU - Kurokawa, Tatsuo

PY - 2013/12

Y1 - 2013/12

N2 - Objective: The compensation scheme for adverse drug reactions in Japan was implemented more than three decades ago as relief system by regulatory agencies. Because of the high frequency of adverse drug reactions, anticancer drugs have been excluded from coverage by the relief system since its implementation. Requests have recently been made by some patient advocates for the expansion of relief coverage to include anticancer drugs. In response to these requests, the Ministry of Health, Labor and Welfare of Japan established a committee to discuss relief from anticancer drug-induced health damages in June 2011. Methods: We conducted comprehensive research into the compensation scheme for adverse drug reactions in the world.We also investigated the situation of compensation and the committee for discussing inclusion of anticancer drugs into the relief system in Japan. Results: Many countries including the United States and UK do not have relief or compensation schemes for no-fault compensation. We investigated whether a no-fault compensation system exists in Nordic countries (Sweden, Denmark, Norway and Finland), France, Germany, New Zealand and Taiwan in the world, although they offer different services from Japan.We also reviewed current situation and the fundamental difficulties associated with including anticancer drugs in the systems in Japan. Conclusions: The present study investigated the current situation and the fundamental difficulties associated with including anticancer drugs in the systems in Japan and pointed out part of the reason why the committee could not conclude involvement of anticancer drugs in the relief system.

AB - Objective: The compensation scheme for adverse drug reactions in Japan was implemented more than three decades ago as relief system by regulatory agencies. Because of the high frequency of adverse drug reactions, anticancer drugs have been excluded from coverage by the relief system since its implementation. Requests have recently been made by some patient advocates for the expansion of relief coverage to include anticancer drugs. In response to these requests, the Ministry of Health, Labor and Welfare of Japan established a committee to discuss relief from anticancer drug-induced health damages in June 2011. Methods: We conducted comprehensive research into the compensation scheme for adverse drug reactions in the world.We also investigated the situation of compensation and the committee for discussing inclusion of anticancer drugs into the relief system in Japan. Results: Many countries including the United States and UK do not have relief or compensation schemes for no-fault compensation. We investigated whether a no-fault compensation system exists in Nordic countries (Sweden, Denmark, Norway and Finland), France, Germany, New Zealand and Taiwan in the world, although they offer different services from Japan.We also reviewed current situation and the fundamental difficulties associated with including anticancer drugs in the systems in Japan. Conclusions: The present study investigated the current situation and the fundamental difficulties associated with including anticancer drugs in the systems in Japan and pointed out part of the reason why the committee could not conclude involvement of anticancer drugs in the relief system.

KW - Adverse drug reactions

KW - Anticancer drug

KW - Compensation

KW - Oncology

KW - Relief system

UR - http://www.scopus.com/inward/record.url?scp=84889058436&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84889058436&partnerID=8YFLogxK

U2 - 10.1093/jjco/hyt146

DO - 10.1093/jjco/hyt146

M3 - Article

C2 - 24068711

AN - SCOPUS:84889058436

VL - 43

SP - 1273

EP - 1281

JO - Japanese Journal of Clinical Oncology

JF - Japanese Journal of Clinical Oncology

SN - 0368-2811

IS - 12

M1 - hyt146

ER -